EMA sets up infrastructure for real-world monitoring of COVID treatments and vaccines

The European Medicines Agency (EMA) announced on 21 July, 2020, that it was establishing infrastructure to support the monitoring of the efficacy and safety of COVID-19 treatments and vaccines when used in day-to-day clinical practice. The move comes as the EMA has recently signed three contracts for observational research with academic and private partners to effectively monitor vaccines in the real world as soon as they are authorised, and support the safe and effective use of COVID-19 vaccines and medicines.

Read more here.